X-group (possible homology)

210 Ntn/PP2C

Open in classification tree →

Ligands and drugs

21,716

Member domains

6,058

with ligand contacts (≤ 4 Å)

27.9% of members

5,305

with DrugDomain annotations

24.4% of members

1,594

with a DrugBank compound

7.3% of members

Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.

Chemical profile

ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.

177

Proteins with classified ligands

Superclasses bound (of 23)

7.8

Superclasses per 20 proteins

broader than 53% of the 256 X-groups with enough proteins to compare (median 7.6)

The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.

Superclass	Proteins	Expected	Ratio	Significance
Organic acids and derivatives	73	27.0	2.70×	q < 0.0001
Benzenoids	24	12.8	1.88×	q = 6.6e-3
Homogeneous non-metal compounds	67	37.6	1.78×	q < 0.0001
Homogeneous metal compounds	106	85.7	1.24×	q = 5.5e-3
Organoheterocyclic compounds	17	26.9	0.63×	q = 0.06
Lipids and lipid-like molecules	12	19.4	0.62×	q = 0.14
Organic oxygen compounds	20	34.8	0.58×	q = 8.8e-3
Organic nitrogen compounds	1	5.6	0.18×	q = 0.08
Nucleosides, nucleotides, and analogues	4	48.2	0.08×	q < 0.0001
Organometallic compounds	1	0.3	4.02×	not tested
Organosulfur compounds	10	3.6	2.79×	not tested

enriched (q < 0.05)depleted (q < 0.05)not significantnot tested (expected < 5)

Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.

DrugBank compounds

DrugBank	PDB ligand	Name	Domains
DB00188	BO2	Bortezomib	232
DB00141	NAG	N-Acetylglucosamine	46
DB00142	GLU	Glutamic acid	37
DB08515	SA1	(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE	28
DB00145	GLY	Glycine	25
DB07930	HXD	(3R)-3-HYDROXYDODECANOIC ACID	23
DB16829	A8S	Abscisic Acid	17
DB04732	M1N	N-(4-MORPHOLINE)CARBONYL-B-(1-NAPHTHYL)-L-ALANINE-L-LEUCINE BORONIC ACID	14
DB02691	GCH	Glycocholic acid	11
DB00160	ALA	Alanine	10
DB04296	ONL	5-Oxo-L-Norleucine	10
DB09570	6V8	Ixazomib	10
DB00128	ASP	Aspartic acid	9
DB00130	GLN	L-Glutamine	9
DB01956	TAU	Taurine	9
DB01902	NEN	1-Ethyl-Pyrrolidine-2,5-Dione	8
DB01972	5GP	Guanosine-5'-Monophosphate	8
DB03790	OMT	L-methionine sulfone	8
DB04348	TCH	Taurocholic acid	8
DB07558	CIB	acetylleucyl-leucyl-norleucinal	8

Most frequently bound compounds

PDB ligand	Name	Domains in contact
MGmetal	MAGNESIUM ION	3,172
CL	CHLORIDE ION	1,467
3BV	N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-[(2R,3S,4S)-1,3-dihydroxy-2,6-dimethylheptan-4-yl]-L-phenylalaninamide	259
BO2	N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE	232
04C	1,2,4-trideoxy-4-methyl-2-{[N-(morpholin-4-ylacetyl)-L-alanyl-O-methyl-L-tyrosyl]amino}-1-phenyl-D-xylitol	202
NAmetal	SODIUM ION	199
CAmetal	CALCIUM ION	141
Kmetal	POTASSIUM ION	102
LDZ	N-[(benzyloxy)carbonyl]-L-leucyl-N-[(2S)-4-methyl-1-oxopentan-2-yl]-L-leucinamide	92
NAG	2-acetamido-2-deoxy-beta-D-glucopyranose	72
MNmetal	MANGANESE (II) ION	63
GLU	GLUTAMIC ACID	47
GLY	GLYCINE	33
GQK	(2~{S})-3-(4-methoxyphenyl)-~{N}-[(2~{S},3~{R})-4-methyl-3,4-bis(oxidanyl)-1-phenyl-pentan-2-yl]-2-[[(2~{S})-2-(2-morpholin-4-ylethanoylamino)propanoyl]amino]propanamide	30
6N5	~{N}-[(2~{S})-1-[[(2~{S})-3-(4-methoxyphenyl)-1-[[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]amino]-1-oxidanylidene-propan-2-yl]amino]-1-oxidanylidene-propan-2-yl]-1-methyl-5~{H}-indene-2-carboxamide	28
79P	(2~{S})-3-(1~{H}-indol-3-yl)-~{N}-[(2~{S},3~{S},4~{R})-4-methyl-3,5-bis(oxidanyl)-1-phenyl-pentan-2-yl]-2-[[(2~{R})-2-(2-morpholin-4-ylethanoylamino)propanoyl]amino]propanamide	28
SA1	(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE	28
IOD	IODIDE ION	25
39V	N-[(3-methyl-1H-inden-2-yl)carbonyl]-D-alanyl-N-[(2S,4R)-5-hydroxy-4-methyl-3-oxo-1-phenylpentan-2-yl]-L-tryptophanamide	24
6V8	[(1~{R})-1-[2-[[2,5-bis(chloranyl)phenyl]carbonylamino]ethanoylamino]-3-methyl-butyl]boronic acid	24